LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections

BACKGROUND: Recurrent Clostridioides difficile infection (rCDI) is an urgent public health threat associated with significant mortality and medical cost. Microbiota therapy is gaining acceptance as a strategy to reduce rCDI recurrence. We present the final 24-month analysis of clinical safety, effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Orenstein, Robert, Mische, Sarah, Blount, Ken, Bancke, Lindy, Su, Xin, Walsh, Dana, Harvey, Adam, Gonzalez, Carlos, Gerding, Dale N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810069/
http://dx.doi.org/10.1093/ofid/ofz415.2488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810069/
http://dx.doi.org/10.1093/ofid/ofz415.2488

Ejemplares similares